SCHEMBL20128970

SCHEMBL20128970

CCCCCCOCCCCCOS(C)(=O)=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.65
KDM4E B2RXH2 1/20 0.65
USP2 O75604 1/20 0.65
ALDH1A1 P00352 1/20 0.65
LMNA P02545 1/20 0.65
MMP9 P14780 1/20 0.65
ALOX15 P16050 1/20 0.65
CA1 P00915 10/20 0.57
CA2 P00918 10/20 0.57
CA9 Q16790 8/20 0.57
CA12 O43570 3/20 0.57
CA7 P43166 3/20 0.57
CA14 Q9ULX7 3/20 0.57
CA3 P07451 2/20 0.57
CA4 P22748 2/20 0.57
CA6 P23280 2/20 0.57
CA5A P35218 2/20 0.57
CA5B Q9Y2D0 2/20 0.57
RECQL P46063 2/20 0.55
GLA P06280 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20145734 1.00 TSHR (0.65) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL15923362 1.00 TSHR (0.65) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL17334638 1.00 TSHR (0.65) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL15923328 0.98 TSHR (0.62) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL10584215 0.98 TSHR (0.62) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL10585399 0.98 TSHR (0.62) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL15922913 0.98 TSHR (0.62) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL28421975 0.98 TSHR (0.62) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL15922881 0.96 TSHR (0.65) TSHRKDM4EUSP2ALDH1A1LMNA
SCHEMBL15923068 0.96 TSHR (0.65) TSHRKDM4EUSP2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN TSHR 4013/4885KDM4E 1112/4885USP2 80/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 TSHR 3954/4885KDM4E 1212/4885USP2 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.